Ruxolitinib as front-line therapy in graft versus host disease: Efficacy and safety in children

• Main Authors: Revathi Raj (Author), Venkateswaran Vellaichamy Swaminathan (Author), Satishkumar Meena (Author), Harika Varla (Author), Rumesh Chandar (Author), Balasubramaniam Ramakrishnan (Author), Ramya Uppuluri (Author)
• Format: Book
• Published: Elsevier, 2021-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Ruxolinitib has been used as an effective salvage agent in steroid refractory acute and chronic graft versus host disease (GVHD). We aimed to analyze data on ruxolitinib as front-line therapy in children. Patients and methods: We included children up to 18 years of age who underwent hema...